From The ASCO Value in Cancer Care Task Force Framework
Use of new drugs is being driven by “sometimes unrealistic patient and family expectations that lead clinicians to offer or recommend some of these services, despite the lack of supporting evidence of utility or benefit.”
Cancer patients “overestimate the benefits of treatments that sometimes extend life by only weeks or months or not at all.
From Lowell Schnipper, Chair of the Task Force:
Three months of added life “is not a large enough benefit to trump the greater benefits to many that would have to be foregone to provide it.”
Now watch what Zach Sobrieth, who died of sarcoma, thinks of three months of life.
Use of new drugs is being driven by “sometimes unrealistic patient and family expectations that lead clinicians to offer or recommend some of these services, despite the lack of supporting evidence of utility or benefit.”
Cancer patients “overestimate the benefits of treatments that sometimes extend life by only weeks or months or not at all.
From Lowell Schnipper, Chair of the Task Force:
Three months of added life “is not a large enough benefit to trump the greater benefits to many that would have to be foregone to provide it.”
Now watch what Zach Sobrieth, who died of sarcoma, thinks of three months of life.